This episode exposes the class action lawsuit against DexCom $DXCM after unauthorized changes to its G6 and G7 glucose sensors sparked FDA warnings, tragic outcomes, and a brutal stock plunge. We break down how misleading safety claims and insider stock sales may have violated securities laws. Ideal for medtech investors, financial sleuths, and patient advocates. Expect sharp takes, real cases, and deep accountability.

Visit ZLK.com for more info.

Add our WhatsApp Channel.

We’re not lawyers or accountants, so don’t take this as legal or financial advice.